Vir Biotechnology stock gains on conference catalyst

Published on 09/03/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vir Biotechnology stock gained after a new 52-week high and a conference appearance. MarketBeat also cites a close of USD 11.63 on September 1, 2026, with market cap at USD 1.97 billion.

Editorialfoto eines Börsenhandelsraums mit Kurscharts auf großen Bildschirmen — Börsen-Editorial-Szene im Trading-Saal illustriert den Aktienkurs von Virbac S.A., FR0000031577, mit passenden Pharma-Branchencharts, Illustration mit AI erstellt.

Vir Biotechnology stock (ISIN US92764N1028) closed at USD 11.63 on September 1, 2026, after a 6.31 percent daily gain and a fresh 52-week high of USD 11.74. According to MarketBeat data cited by ad hoc news, the share price was still close to the top of its one-year range.

Conference trade stays in view

The same report links the move to Vir Biotechnology's planned appearance at the Morgan Stanley 24th Annual Global Healthcare Conference in early September 2026. MarketBeat also puts the average price target at USD 21.57 and describes the consensus as Moderate Buy.

A second detail matters for investors: Leerink Partners lifted its target to USD 21.00 from USD 20.00 and kept an Outperform rating. That leaves the stock at a steep discount to the consensus target, even after the recent rebound.

Quarterly numbers set the tone

Vir Biotechnology last reported quarterly earnings on August 5, 2026, with EPS of USD 0.47 versus a consensus estimate of USD 0.33. Revenue reached USD 238.95 million, above the USD 135.88 million analyst view, while the quarterly revenue increase was reported at 19,582.5 percent year on year.

The scale is what stands out. A market value of USD 1.97 billion as of September 1, 2026, sits against quarterly revenue of USD 238.95 million, giving the latest numbers more weight than the conference headline alone.

Go deeper

Vir Biotechnology stock and the latest filings

A closer look at the latest quarter, analyst view and market reaction helps frame the current setup for Vir Biotechnology stock.

Vir Biotechnology topic page

VIR and its pipeline

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on therapies for infectious diseases. Its pipeline includes candidates for influenza A, COVID-19, HIV, hepatitis B and tuberculosis.

Stock level on September 1, 2026

Vir Biotechnology stock traded at USD 11.63 on September 1, 2026, with a market capitalization of USD 1.97 billion. The 52-week high at USD 11.74 kept the shares within a narrow band near the recent peak.